Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Preliminary Evaluations of the Antibacterial Activity of Tasmannia lanceolata against Bacillus anthracis: Natural Resource Probing to Prevent Anthrax

    wadmin1By wadmin1September 1, 2019Updated:August 10, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Cameron Jay Lee1, Mitchell Henry Wright2,*, Anthony Carlson Greene1, Huda Aldosary1, Ian Edwin Cock1,3,*

    1School of Environment and Science, Griffith University, Brisbane, Queensland, AUSTRALIA.

    2Department of Research and Development, First Choice College, Gold Coast, Queensland, AUSTRALIA.

    3Environmental Futures Research Institute, Griffith University, Brisbane, Queensland, AUSTRALIA.

    Pharmacognosy Communications,2019,9,4,124-129.
    DOI:10.5530/pc.2019.4.26
    Published:September 2019
    Type:Original Article

    ABSTRACT

    Introduction: Bacillus anthracis is bacterial cause of the highly fatal, zoonotic disease anthrax. Tasmanian pepper (Tasmannia lanceolata) has been previously documented for its antiseptic properties against other pathogenic bacteria. This study sought to investigate the effectiveness of T. lanceolata as an inhibitory agent against B. anthracis. Methods: Tasmannia lanceolata berry and leaf extracts were prepared with either water or methanol as the extraction solvent. Growth inhibition was assessed against B. anthracis strain PMO through disc diffusion as assaying. The relative MIC values of each extract was quantified to evaluate efficacy as a sterilant. The degree of toxicity of each extract was achieved using the widely used Artemia franciscana nauplii bioassay. Results: T. lanceolata leaf extracts inhibited the growth of B. anthracis in the disc diffusion assay, with MIC values of 2333 and 1873 μg/mL respectively. In contrast, the T. lanceolata berry extracts were completely devoid of growth inhibitory activity. All T. lanceolata extracts (both berry and leaf) were non-toxic (LC50 values substantially >1000 μg/mL) as determined via the Artemia franciscana bioassay. Conclusion: T. lanceolata berry and leaf extracts are not only non-toxicity, but also had moderate growth inhibitory bioactivity against B. anthracis, highlighting their potential in the treatment of anthrax.

    Keywords:Anthrax, antioxidant, Bacillus anthracis, Tasmanian pepper, Tasmannia lanceolata, Zoonotic
    Download PDF

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up